logo-loader

Immuron targets cash injection

Published: 12:00 08 Jun 2017 AEST

shutterstock_263120237
Immuron is focused on gut mediated diseases

Immuron (ASX:IMC) has been granted a trading halt by the ASX, pending details of a capital raising.

Immuron is developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases.

The halt will remain in place until the opening of trade on Tuesday 13th June 2017, or earlier if an announcement is made to the market.

Immuron hails record monthly sales of Travelan

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®. For August, the company registered Australian sales amounting to A$1.18 million, representing a...

on 14/9/23